Cabaletta Bio, Inc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of investors who purchased Cabaletta Bio, Inc. (NASDAQ: CABA): (a) common stock pursuant and/or traceable to documents issued in connection with the Company’s initial public offering conducted on or about October 24, 2019; and/or (b) securities between October 24, 2019 and December 13, 2021, both dates inclusive.
According to the Cabaletta lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) top-line data of the Phase 1 Clinical Trial indicated that Cabaletta’s lead product candidate, DSG3-CAART, had, among other things, worsened certain participants’ disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion; (ii) accordingly, DSG3-CAART was not as effective as the Company had represented to investors; (iii) therefore, the Company had overstated DSG3-CAART’s clinical and/or commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
“Cabaletta Bio, Inc.”
If you suffered a loss in Cabaletta you have until April 29, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.